{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:04:03Z","timestamp":1789563843979,"version":"build-2803163510"},"reference-count":8,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Homologous recombination repair (HRR) alterations define a heterogeneous subgroup of metastatic castration-resistant prostate cancer. TALAPRO-2 established randomized benefit of talazoparib plus enzalutamide within HRR-deficient disease, but it did not determine whether treated HRR-deficient patients remain prognostically disadvantaged relative to biomarker-defined enzalutamide-alone reference groups. We performed exploratory trial-internal benchmarking using reconstructed individual patient data from published TALAPRO-2 Kaplan\u2013Meier curves, with different endpoint-specific reference groups for radiographic progression-free survival (rPFS) and overall survival (OS). With enzalutamide alone, HRR-deficient disease had shorter rPFS than HRR-non-deficient disease (16.4 vs 22.3\u00a0months; HR 1.42, 95% CI 1.00\u20132.00) and shorter OS than disease with no HRR alteration detected (30.9 vs 37.7\u00a0months; HR 1.23, 95% CI 0.89\u20131.71). With talazoparib plus enzalutamide, corresponding medians were 27.9 and 45.8\u00a0months; cross-benchmark HRs were 0.73 (95% CI 0.50\u20131.07) and 0.66 (95% CI 0.46\u20130.96). These non-randomized comparisons are descriptive and do not establish equivalence, superiority, or prognostic normalization.<\/jats:p>","DOI":"10.1093\/jjco\/hyag152","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:27:49Z","timestamp":1788521269000},"source":"Crossref","is-referenced-by-count":0,"title":["Survival benchmarking of talazoparib plus enzalutamide in homologous recombination repair-deficient metastatic castration-resistant prostate cancer: a reconstructed individual patient data analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3003-3833","authenticated-orcid":false,"given":"Hiroki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-1580","authenticated-orcid":false,"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Tsukahara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091608133683400_ref1","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026091608133683400_ref2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026091608133683400_ref3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"2026091608133683400_ref4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"2026091608133683400_ref5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"2026091608133683400_ref6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2026091608133683400_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-025-01194-w","article-title":"Time-dependent comparative effectiveness of first-line treatment for metastatic clear cell renal cell carcinoma: a restricted mean survival time-based network meta-analysis","volume":"21","author":"Fukushima","year":"2026","journal-title":"Target Oncol"},{"key":"2026091608133683400_ref8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.euros.2026.01.013","article-title":"Re-evaluating treatments for advanced urothelial carcinoma using restricted mean survival time: a systematic review and network meta-analysis","volume":"85","author":"Yajima","year":"2026","journal-title":"Eur Urol Open Sci"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag152\/71122386\/hyag152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag152\/71122386\/hyag152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:13:43Z","timestamp":1789560823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag152\/8802006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":8,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag152","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"hyag152"}}